Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)

• Status: WITHDRAWN
• Trial end date: 2026-09-22

Summary

This phase II trial tests the safety and effectiveness of giving chemotherapy with or without venetoclax and/or navitoclax for the treatment of patients with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL). Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax and navitoclax are in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. They may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving chemotherapy with or without venetoclax and/or navitoclax may be effective treatments for patients with newly diagnosed T-ALL or T-LBL.

• Phase: PHASE2

Details

• Lead Sponsor: National Cancer Institute (NCI)
• Treatments: Asparaginase; auricularum; azathiopurine; Biopsy; calaspargase pegol; Calcium Dobesilate; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; dexamethasone 21-phosphate; dexamethasone acetate; Doxorubicin; Magnetic Resonance Spectroscopy; Mercaptopurine; merphos; Methotrexate; navitoclax; nelarabine; pegaspargase; Phantoms, Imaging; Specimen Handling; Spinal Puncture; Thioguanine; venetoclax; Vincristine; X-Rays